Recombinant porcine insulin is produced in yeast in a tag-free format, ensuring correct disulfide bond formation and native biological activity. Porcine insulin is structurally nearly identical to human insulin—differing by only a single amino acid—making it a highly potent regulator of cell metabolism and growth in mammalian culture systems.

In vitro, porcine insulin acts as a key mitogenic and survival factor by binding to the insulin receptor (IR) and the insulin-like growth factor-1 (IGF-1) receptor. This binding triggers essential intracellular cascades, including the PI3K/Akt and MAPK pathways, which drive glucose uptake, protein synthesis, and cell cycle progression. By utilizing a recombinant yeast expression system, this product provides a high-purity, animal-origin free (AOF) alternative to tissue-derived insulin, eliminating the risk of adventitious agents while maintaining superior batch-to-batch consistency.